NCT02757326 - ABC294640 (Opaganib) in Refractory / Relapsed Multiple Myeloma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 13, 2016

Primary Completion Date

May 31, 2019

Study Completion Date

May 31, 2019

Conditions

Multiple Myeloma

Interventions

DRUG

Opaganib

Opaganib, \[3-(4-chlorophenyl)-adamantane-1-carboxylic acid (N-(Pyridin-4-ylmethyl)pyridine-4-carboxamide) amide, hydrochloride salt\] is an orally available inhibitor of the enzyme SK2.

Trial Locations (1)

27705

Duke University Medical Center, Durham